Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market depressed on Cyberonics new market ploy

This article was originally published in Clinica

Executive Summary

Shares in Cyberonics, a US device company aimed at managing epilepsy and other neurological disorders through pulsed electrical stimulation of the vagus nerve, fell to a 52-week low following the announcement of its third quarter results and a plan to tap into the market for depression therapy. Industry analysts called the plan "over-aggressive", addressing a market that will not be large enough to compensate the company for the size of investment it is making.

You may also be interested in...



Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel